Short Communication
A Genome-wide Association Study of Early-Onset Breast Cancer Identifies PFKM as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for Breast Cancer at Any Age
Habibul Ahsan, Jerry Halpern, Muhammad G. Kibriya, Brandon L. Pierce, Lin Tong, Eric Gamazon, Valerie McGuire, Anna Felberg, Jianxin Shi, Farzana Jasmine, Shantanu Roy, Rachelle Brutus, Maria Argos, Stephanie Melkonian, Jenny Chang-Claude, Irene Andrulis, John L. Hopper, Esther M. John, Kathi Malone, Giske Ursin, Marilie D. Gammon, Duncan C. Thomas, Daniela Seminara, Graham Casey, Julia A. Knight, Melissa C. Southey, Graham G. Giles, Regina M. Santella, Eunjung Lee, David Conti, David Duggan, Steve Gallinger, Robert Haile, Mark Jenkins, Noralane M. Lindor, Polly Newcomb, Kyriaki Michailidou, Carmel Apicella, Daniel J. Park, Julian Peto, Olivia Fletcher, Isabel dos Santos Silva, Mark Lathrop, David J. Hunter, Stephen J. Chanock, Alfons Meindl, Rita K. Schmutzler, Bertram Müller-Myhsok, Magdalena Lochmann, Lars Beckmann, Rebecca Hein, Enes Makalic, Daniel F. Schmidt, Quang Minh Bui, Jennifer Stone, Dieter Flesch-Janys, Norbert Dahmen, Heli Nevanlinna, Kristiina Aittomäki, Carl Blomqvist, Per Hall, Kamila Czene, Astrid Irwanto, Jianjun Liu, Nazneen Rahman, Clare Turnbull, for the Familial Breast Cancer Study, Alison M. Dunning, Paul Pharoah, Quinten Waisfisz, Hanne Meijers-Heijboer, Andre G. Uitterlinden, Fernando Rivadeneira, Dan Nicolae, Douglas F. Easton, Nancy J. Cox and Alice S. Whittemore
Habibul Ahsan
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Jerry Halpern
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Muhammad G. Kibriya
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Brandon L. Pierce
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Lin Tong
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Eric Gamazon
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Valerie McGuire
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Anna Felberg
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Jianxin Shi
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Farzana Jasmine
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Shantanu Roy
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Rachelle Brutus
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Maria Argos
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Stephanie Melkonian
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Jenny Chang-Claude
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Irene Andrulis
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
John L. Hopper
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Esther M. John
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Kathi Malone
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Giske Ursin
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Marilie D. Gammon
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Duncan C. Thomas
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Daniela Seminara
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Graham Casey
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Julia A. Knight
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Melissa C. Southey
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Graham G. Giles
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Regina M. Santella
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Eunjung Lee
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
David Conti
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
David Duggan
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Steve Gallinger
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Robert Haile
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Mark Jenkins
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Noralane M. Lindor
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Polly Newcomb
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Kyriaki Michailidou
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Carmel Apicella
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Daniel J. Park
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Julian Peto
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Olivia Fletcher
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Isabel dos Santos Silva
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Mark Lathrop
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
David J. Hunter
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Stephen J. Chanock
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Alfons Meindl
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Rita K. Schmutzler
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Bertram Müller-Myhsok
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Magdalena Lochmann
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Lars Beckmann
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Rebecca Hein
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Enes Makalic
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Daniel F. Schmidt
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Quang Minh Bui
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Jennifer Stone
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Dieter Flesch-Janys
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Norbert Dahmen
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Heli Nevanlinna
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Kristiina Aittomäki
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Carl Blomqvist
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Per Hall
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Kamila Czene
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Astrid Irwanto
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Jianjun Liu
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Nazneen Rahman
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Clare Turnbull
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Alison M. Dunning
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Paul Pharoah
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Quinten Waisfisz
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Hanne Meijers-Heijboer
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Andre G. Uitterlinden
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 32Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia; 33Norway Cancer Registry, Norway; Departments of 34Public Health and Primary Care and 35Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge; 36Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine; 37Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London; 38Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 39Centre National de Genotypage, Evry; 40Fondation Jean Dausset–CEPH, Paris, France; Departments of 41Obstetrics and Gynecology, 42Clinical Genetics, and 43Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 44Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 45Human Genetics Division, Genome Institute of Singapore, Singapore, Singapore; 46Department of Clinical Genetics, VU University Medical Center, Division of Oncogenetics, Amsterdam; and 47Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
Fernando Rivadeneira
1Center for Cancer Epidemiology and Prevention; Departments of 2Health Studies, 3Medicine, and 4Human Genetics; 5Comprehensive Cancer Center, University of Chicago, Chicago, Illinois; 6Department of Health Research and Policy, Stanford University School of Medicine; 7Stanford Cancer Institute, Stanford; 8Cancer Prevention Institute of California, Fremont; 9Department of Preventive Medicine, University of Southern California, Los Angeles; 10Stanford Cancer Institute, Palo Alto, California; 11Epidemiology and Genetics Research Program; 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 13Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 14Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 15Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York; 16Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix; 17Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; 18Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts; 19Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; 20Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München; 21Max Planck Institute of Psychiatry, Munich; 22Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, 23PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne; 24Foundation for Quality and Efficiency in Health Care, Cologne; 25Department of Cancer Epidemiology/Clinical Cancer Registry; 26Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg; 27Department of Psychiatry, University of Mainz, Mainz, Germany; 28Samuel Lunenfeld Research Institute; 29Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; 30Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health; 31Genetic Epidemiology Laboratory, Department of Pathology, U